To date, no direct comparisons of safety and efficacy have been made between TC and EC, so this study is aimed at comparing the safety profiles of EC versus TC to make a better chemotherapy choice for node-negative, HR-positive, HER2-negative breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.